|
|
|
|
|
|
by estearum
27 days ago
|
|
|
As demonstrated, the people who struggle with this just don't actually have any actual curiosity. "Par for the course" indeed! Here's a step by step guide for you: 1. Google "Pfizer covid vaccine studies CDC" 2. Click top result: https://www.cdc.gov/acip/grade/covid-19-pfizer-biontech-vacc... 3. Scroll to results: > Outcomes of interest included individual benefits and harms. Indirect effects of vaccination (e.g., societal benefits) were not considered... > In the Phase II/III RCT, using data on all blinded follow-up (up to 6 months or the unblinding date of March 13, 2021), the Pfizer-BioNTech COVID-19 vaccine reduced symptomatic COVID-19 when compared to placebo (vaccine efficacy: 91.1% (95% CI 88.8–93.1%)) (Table 3a). For hospitalization due to COVID-19, 31 events occurred, all in the placebo group. Vaccine efficacy against hospitalization due to COVID-19 was 100% (95% CI 87.6–100%) (Table 3b). Deaths due to COVID-19 were uncommon, one in the vaccine group and six in the placebo group (83% (-39–98%)) (Table 3c). Numbers of SAEs were comparable between the vaccine group and the placebo group across the two RCTs (Phase II/III: 268/21,926 (1.2%) vs. 268/21,921 (1.2%); Phase I: 1/24 (4.2%) vs. 0/6 (0.0%)); there were no cases of vaccine-associated enhanced disease or vaccine-related deaths (Table 3e). Grade ≥3 reactions generally were not uncommon and occurred more frequently in the vaccine than placebo groups (Table 3f). |
|
|